Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Biofrontera (BFRI) over the last 5 years, with Q3 2025 value amounting to $236000.0.

  • Biofrontera's Share-based Compensation fell 1805.56% to $236000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $961000.0, marking a year-over-year increase of 137.13%. This contributed to the annual value of $1.0 million for FY2024, which is 248.8% down from last year.
  • According to the latest figures from Q3 2025, Biofrontera's Share-based Compensation is $236000.0, which was down 1805.56% from $187000.0 recorded in Q2 2025.
  • Biofrontera's Share-based Compensation's 5-year high stood at $551000.0 during Q2 2022, with a 5-year trough of $129000.0 in Q4 2021.
  • In the last 5 years, Biofrontera's Share-based Compensation had a median value of $249000.0 in 2023 and averaged $294187.5.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 19689.92% in 2022, then crashed by 5299.46% in 2023.
  • Biofrontera's Share-based Compensation (Quarter) stood at $129000.0 in 2021, then surged by 196.9% to $383000.0 in 2022, then crashed by 40.47% to $228000.0 in 2023, then surged by 31.14% to $299000.0 in 2024, then decreased by 21.07% to $236000.0 in 2025.
  • Its Share-based Compensation was $236000.0 in Q3 2025, compared to $187000.0 in Q2 2025 and $239000.0 in Q1 2025.